IDH1 and central nervous system cancer: In fact, the current WHO classification of central nervous system tumors mandates integration of molecular markers, including IDH1/2 mutations, 1p/19q codeletion status, ATRX and TP53 alterations, and MGMT promoter methylation, as essential criteria for accurate diagnosis.